Skip to main content

Recovery From Anti-NMDAR Encephalitis Continues for Three Years

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 22, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Nov. 22, 2024 -- Recovery from anti-NMDA receptor (anti-NMDAR) encephalitis continues for three years, but deficits persist, according to a study published online Nov. 20 in Neurology.

Juliette Brenner, M.D., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues conducted a large-scale cross-sectional and prospective cohort study to examine the temporal trajectory of anti-NMDAR encephalitis in patients aged older than 16 years who were independent prior to illness onset. Patients completed Patient-Reported Outcome Measures and neuropsychological assessments, and functional outcomes were assessed and compared to references.

Ninety-two patients were included in the study. The researchers observed improvement in cognitive scores with time of assessment, up to 36 months after diagnosis; the most enhanced improvement occurred in the first six months. In 12 prospective patients, this result could be reproduced. Thirty-four percent of patients had a persistent impairment beyond 36 months; 65 percent scored below-average in one or more cognitive domains, although the majority (91 percent) had a favorable outcome as measured by the modified Rankin Scale. Memory and language were the most affected. Persistent self-reported complaints were seen in emotional well-being, social functioning, energy levels, and quality of life. Some patients did not resume school/work or required adjustments (30 and 18 percent, respectively). There were associations observed for resuming school/work with processing speed and well-being.

"Our study found that recovery from anti-NMDAR encephalitis takes longer than previously thought, up to three years, and often with lingering memory, emotional, and social problems," coauthor Maarten Titulaer, M.D., Ph.D., also of the Erasmus University Medical Center, said in a statement. "Identifying subtle cognitive, social, or emotional symptoms is imperative, especially since this disease primarily affects young adults. The impact on their school, work, and social life can be immense."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

Read this next

CDC IDs Trends in Pediatric Flu Deaths With Influenza-Linked Encephalopathy

MONDAY, March 3, 2025 -- During the 2010-2011 to 2024-2025 influenza seasons, 9 percent of pediatric influenza-associated deaths had influenza-associated encephalopathy or...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.